Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
-
Therapeutic Areas
Our expertise in the industry
Merck’s Chronic Cough Med Gefapixant Receives A Red Flag From the FDA, Requests For More Data On 24th January 2022, Merck & Co. announced FDA rejection for its New Drug Application (NDA) of...
What is Glioblastoma Multiforme? Glioblastoma multiforme (GBM) (also called glioblastoma) is a fast-growing type of gliomas, which are the most common form of primary tumors of the central nerv...
The present Glioblastoma multiforme (GBM) market has several unmet needs. Poor prognosis, 10-15 months median survival rate, no curative treatment to the patients, limited treatment options, drug ...
Headaches. Blurred vision. Nausea. No or poor appetite. Behavioral changes. Trouble thinking. These are some common problems people experience in their daily lives; however, are easy to write off ...
Bexion Pharmaceuticals’ Early-Stage Cancer Drug, BXQ-350 Hailed as Game Changer For the Treatment of solid tumors and gliomas Bexion Pharmaceuticals’ investigational cancer treatment, BXQ-350, i...
Idera Pharmaceuticals Present Positive Phase I Data for their Drug candidate IMO-2125 Idera Pharmaceuticals announced final results from the dose-selection phase of an ongoing Phase 1/2 trial inves...
The Pharma and Biotech Healthcare market has been an ever-changing industry in terms of...
The organ on a chip is a microfluidic culture device that recapitulates the complicated...
An Intraocular Lens implant is a synthetic, artificial lens placed inside the eye...
Ankylosing Spondylitis is a form of arthritis that primarily affects the spine. It caus...
Immunotherapy also called biologic therapy, is a type of cancer treatment that boosts t...
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
